Label-free imaging of cerebral β-amyloidosis with extended-focus optical coherence microscopy

J Neurosci. 2012 Oct 17;32(42):14548-56. doi: 10.1523/JNEUROSCI.0925-12.2012.

Abstract

We demonstrate label-free imaging of cerebral β-amyloidosis ex vivo and in a living mouse model of Alzheimer's disease using extended-focus Fourier domain optical coherence microscopy (xfOCM). xfOCM provides 3D, high-resolution images of individual β-amyloid plaques in the brain parenchyma and vasculature and requires no staining of the alzheimeric sample under investigation. xfOCM also opens the possibility to perform minimally invasive studies of β-amyloid pathology in vivo, without the use of labeling methods, which potentially confound experimental findings.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / genetics
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / chemistry*
  • Amyloid beta-Peptides / genetics
  • Animals
  • Cerebral Amyloid Angiopathy / genetics
  • Cerebral Amyloid Angiopathy / metabolism
  • Cerebral Amyloid Angiopathy / pathology*
  • Disease Models, Animal*
  • Fourier Analysis
  • Humans
  • Mice
  • Mice, Transgenic
  • Microscopy, Confocal / instrumentation
  • Microscopy, Confocal / methods
  • Neuroimaging / instrumentation
  • Neuroimaging / methods
  • Plaque, Amyloid / genetics
  • Plaque, Amyloid / pathology
  • Staining and Labeling
  • Tomography, Optical Coherence / instrumentation
  • Tomography, Optical Coherence / methods*

Substances

  • Amyloid beta-Peptides